VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Earnings for VectivBio Holding AG (VECT)
Earnings in 2022 (TTM): $-93,628,000
According to VectivBio Holding AG's latest financial reports the company's current earnings (TTM) are $-93,628,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of VectivBio Holding AG
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-93,628,000 | $-93,735,000 |
| 2021 | $-86,945,000 | $-87,009,000 |
| 2020 | $-59,943,000 | $-60,497,000 |
| 2019 | $-23,481,000 | $-23,531,000 |